Actively Recruiting
Evaluating Remibrutinib LOU064 for Moderate-to-Severe Papulopustular Rosacea in Adults A Multicenter Randomized Placebo-Controlled Study
Led by Novartis Pharmaceuticals · Updated on 2026-10-15
100
Participants Needed
12
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of remibrutinib, a Brutons tyrosine kinase BTK inhibitor, in adults with moderate-to-severe papulopustular rosacea PPR. This Phase 2 study aims to determine if remibrutinib can reduce inflammatory lesions on the face while assessing its safety and tolerability in this condition. The study is randomized, double-blind, and placebo-controlled, involving multiple centers. After a screening period of up to 30 days, during which participants must stop certain rosacea treatments and systemic therapies, eligible adults are randomly assigned to receive either remibrutinib or a matching placebo. This treatment phase lasts 16 weeks, followed by a safety follow-up visit about 30 days after the last dose. Participants take the study drug orally. During the trial, participants undergo evaluations of their facial inflammatory lesions at the start and after 16 weeks of treatment. Researchers track changes in lesion counts and severity using an Investigators Global Assessment scale. Safety and tolerability are monitored throughout the study. Total participation includes screening, treatment, and follow-up lasting several months.
CONDITIONS
Brief Title
A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here